Apimeds Pharmaceuticals US FY 2025: Revenue $0 Net loss $6M, EPS $(0.55) — 10-K Summary
I'm LongbridgeAI, I can summarize articles.Apimeds Pharmaceuticals US, Inc. reported a net loss of $6M for FY 2025 on $0 revenue, compared to a $1.4M loss in FY 2024. The diluted EPS was $(0.55) based on 10.88M shares. The company completed its NYSE IPO on May 12, 2025, raising approximately $11.6M. It also acquired MindWave, expanding into digital assets. R&D spending reached $1.6M, with plans for further funding and clinical advancements through 2026.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $6M for fiscal 2025 on revenue of $0 compared with a net loss of $1.4M and no revenue in fiscal 2024; diluted loss per share was $(0.55) in 2025 based on 10.88M weighted‑average shares — 10-K Summary.
Financial Highlights
- Revenue was $0 for FY 2025 and FY 2024 (no revenue from biopharmaceutical or MindWave operations).
- Net income: Net loss of $6.0M for FY 2025, compared with net loss of $1.4M for FY 2024.
- Diluted earnings per share: $(0.55) per share for FY 2025 (basic and diluted), based on 10.88M weighted‑average shares.
Business Highlights
- IPO and public listing: Completed NYSE IPO on May 12, 2025, providing public market access and approximately $11.6M in net proceeds to support operations.
- Strategic merger expansion: Acquired MindWave on Dec. 1, 2025, creating a dual‑segment company that adds digital asset operations and blockchain ecosystem management.
- Operational scale‑up: Ramped biopharma activities in 2025, with $1.6M in R&D spend, CRO engagements, and $2M in prepaid clinical services for Apitox trials.
- Digital asset monetization & activity: Realized and unrealized gains from NILA token sales and BTC holdings bolstered non‑operating income and provided additional liquidity options.
- Near‑term funding and clinical plan: Management intends to draw remaining PIPE tranches, continue token sales, and advance Apitox manufacturing and clinical work through 2026.
Original SEC Filing: Apimeds Pharmaceuticals US, Inc. [ APUS ] - 10-K - May. 04, 2026